Dana Williams
Nurse Practitioner · Junction City, KSNPI 1891839478
Payments from drug & device makers
Across 85 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$216
- Amgen$194
- AbbVie$192
- Biohaven Pharmaceuticals, Inc.$184
- Lilly USA, LLC$164
- Astellas Pharma US Inc$126
- plus $378 from 13 others
What the payments were for
- Food & beverage$1,36994%
- Education$856%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 15 | $216 |
| Amgen | 12 | $194 |
| AbbVie | 12 | $192 |
| Biohaven Pharmaceuticals, Inc. | 10 | $184 |
| Lilly USA, LLC | 10 | $164 |
| Astellas Pharma US Inc | 5 | $126 |
| Organogenesis Inc. | 3 | $74 |
| Boehringer Ingelheim | 4 | $64 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $57 |
| Pfizer | 2 | $26 |
| Apria Healthcare LLC | 1 | $24 |
| Genentech USA, Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Novartis | 1 | $19 |
| Tactile Systems Technology Inc | 1 | $17 |
| AstraZeneca | 1 | $15 |
| Convatec Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| Mylan Specialty L.p. | 1 | $12 |
How this compares
$1,454 in reported general payments places this provider in the 80th percentile of 1,326 nurse practitioner providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 23 | $27,634 |
| TrulicityDulaglutide | 18 | $24,776 |
| LinzessLinaclotide | 28 | $22,919 |
| MounjaroTirzepatide | 22 | $21,332 |
| EliquisApixaban | 26 | $19,111 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $17,935 |
| JanuviaSitagliptin Phosphate | 17 | $15,192 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $13,822 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $4,282 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 72 | $2,997 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $2,652 |
| Doxepin Hcl | 11 | $1,985 |
| Atorvastatin Calcium | 214 | $1,923 |
| Levothyroxine Sodium | 200 | $1,803 |
| Pregabalin | 35 | $1,502 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $164 | $46,10840 claims |
| Novo NordiskOzempic | $216 | $27,63423 claims |
| AbbVieLinzess, Synthroid | $192 | $23,88639 claims |
| PfizerEliquis | $26 | $19,11126 claims |
| AstraZenecaSymbicort | $15 | $4,28213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,326 nurse practitioner providers in Kansas.
Other nurse practitioner in Junction City
- Gary GrafTopeka$726K
- Sarah FitzmauriceKansas City$247K
- Anna ShortRoeland Park$215K
- Shannon GreggTopeka$140K
- Morteza RabiiOverland Park$88K
- Constance JacobWichita$65K
- Michelle KirkHutchinson$58K
- Catherine PowellWichita$50K
- Lori RanalloWestwood$48K
- Kristyn MilburnPleasanton$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.